Business Wire

Exclusive Networks Appoints Jesper Trolle as CEO

15.9.2020 10:00:00 EEST | Business Wire | Press release

Share

Exclusive Networks (‘Exclusive’) today announced the appointment of Jesper Trolle as CEO with immediate effect. Trolle joins Exclusive from ECS Arrow Electronics, where he is currently President of the Americas, and will be responsible for driving the next phase of growth at the company and upscaling the business. Trolle takes over from Olivier Breittmayer who becomes a non-executive Board member of Exclusive. The move is part of a planned succession strategy and Trolle will work alongside Breittmayer for the next three months to ensure a smooth transition.

Vastly experienced and recognised as an entrepreneurial business leader within the IT industry, Trolle has spent over 28 years working in the sector, initially within the reseller community, before moving into distribution. In 2001 he founded Next Denmark A/S which was acquired by DNS Denmark, which in turn was acquired by Arrow in 2005. Since then, Jesper has held a number of diverse positions in multiple locations within Arrow, seeing rapid success and progression, including stints in Germany running central and eastern Europe, and Paris, running north-west Europe. He took up the role as Arrow’s President Americas in 2017, based out of Denver, Colorado, where he has successfully grown a double-digit $bn business.

Speaking about the appointment, Breittmayer said, “Jesper was the standout choice following an intensive search and selection process these last six months or so. His cultural and international experience, obvious entrepreneurial DNA, knowledge of upscaling global businesses at pace and empathy with value-based distribution is impressive and refreshing. It is with confidence and a smile that we are getting such a capable person to take over the helm of the business we’ve grown by some 2,000% over the last 17 years.”

Talking of his appointment Trolle added, “Opportunities like this do not come around that often, but in distribution, Exclusive is at the top of the list if they do. I’m delighted to be joining such a successful company with a strong reputation for innovation and exceptional growth. Exclusive is renowned for its disruptive approach and relentless focus on value creation for its partners. When given the opportunity to become a part of the Exclusive family and next phase of its journey, it was an easy and fast decision to make.

“Olivier’s vision of creating the only specialist distributor on a global scale, focused on high performance cybersecurity infrastructure, was imaginative and disruptive – and that vision has become reality. Exclusive continues to buck market trends, growing at pace organically, expanding geographically and still disrupting. The only thing that hasn’t changed or been diluted is the obsession with value, services and specialism. This scale and specialist approach has never before been achieved. My job is clear: turn the global presence into a cybersecurity infrastructure powerhouse, at scale and speed, and it is a challenge I relish, feel qualified to do and very much look forward to,” concluded Trolle.

Michail Zekkos, Partner at Permira, and a member of Exclusive’s Board of Directors, commented, “Olivier is a pioneer and a true inspiration in modern day value-based distribution. It was a hard task to find his natural replacement, but in Jesper we feel we have done just that. He’s exceptionally talented and culturally very aligned to L’Esprit Exclusive. Olivier’s vision of building the Exclusive ‘Network’ of value-based distribution businesses, globally guided but locally delivered, was unique.

“The business has consistently outperformed market growth rates; expanded at breathtaking speed and delivered financial results that are exceptional for the sector. This is a great platform from which Jesper can continue the adventure and scale-out the business, and with his vision, multicultural background and experience of growth at scale we feel confident he is more than able to meet the challenge.

“Myself and the rest of the Exclusive family thank Olivier wholeheartedly for his indelible impact on the company, and welcome him onto the Board of Directors.”

Breittmayer added finally, “It’s not goodbye, it’s à plus tard.”

-ends-

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Exclusive Networks Contact:
Jon Bawden
Cohesive
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye